Case report: purpura in disseminated strongyloidiasis.
Purpuric lesions have been described previously in 10 patients with disseminated strongyloidiasis. We identified three additional patients in whom purpura developed as a manifestation of disseminated strongyloidiasis. Nine (69%) of the 13 patients were men, and the median age of patients was 61 years (range, 32-75 years). Six patients were from the southeastern United States. Six patients had underlying malignancy and four patients had chronic lung disease. All patients had received prior corticosteroids. The parasite was identified in 11 (92%) of 12 patients where stool or sputum examination was performed. Skin biopsies of purpuric lesions were obtained in 12 patients, in 10 (83%) of which larvae were found. Despite recommended treatment with thiabendazole in 12 of 13 patients, 11 (85%) of the patients died, and at least 6 died within 16 days of onset of purpura. Physicians, particularly those in the southeastern United States, should strongly consider the diagnosis of disseminated strongyloidiasis in patients receiving corticosteroids and in whom purpura and systemic toxicity develops.
Chaudhary
K
K
Department of Medicine, University of Tennessee Medical Center at Knoxville 37920-6999.
Smith
R J
RJ
Himelright
I M
IM
Baddour
L M
LM
D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D000328:Adult; D000368:Aged; D000818:Animals; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011693:Purpura / Q000209:etiology* / Q000473:pathology; D013183:Sputum / Q000469:parasitology; D017171:Strongyloides stercoralis / Q000302:isolation & purification; D013322:Strongyloidiasis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000469:parasitology; D013827:Thiabendazole / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D013827:Thiabendazole